A GLP-1 consultation with an eating-disorder history: screen, coordinate, and follow up
An eating-disorder or disordered-eating history deserves a nonstigmatizing assessment before a weight-focused GLP-1 program. New 2026 guidance supports screening and coordinated monitoring; it does not create a blanket FDA contraindication or prove the medicine treats an eating disorder.
A history of an eating disorder or disordered eating should be discussed before joining a weight-focused GLP-1 program, with a plan for coordinated follow-up if medication is considered. The 2026 ADA obesity-evaluation standard supports screening for eating-disorder symptoms, and a 2026 expert consensus recommends screening current and historical disorders around GLP-1 prescribing. Neither source turns all eating-disorder history into an FDA contraindication, and the Wegovy label does not list it as one. The decision remains individual and may involve an eating-disorder specialist.123
Why the history matters without becoming a label ban
Weight-focused treatment can intersect with restrictive behaviors, binge eating, compensatory behaviors, body-image distress, and ongoing recovery. Those patterns are not captured by BMI or a quick medication eligibility form. The ADA’s 2026 adult standard calls for a comprehensive evaluation and validated screening for mental-health conditions, including eating disorders and disordered eating. The newer Delphi paper offers clinical recommendations for GLP-1 use in this context, but it is a consensus exercise in an evidence-developing area—not a randomized proof of safety or benefit for every disorder.12
| Discussion item | What a care team can do | What to avoid assuming |
|---|---|---|
| Current or past eating-disorder diagnosis | Document the history and coordinate with existing clinicians. | That any past diagnosis automatically forbids a GLP-1. |
| Current restrictive or binge patterns | Use appropriate screening and assess treatment goals. | That a medicine treats the pattern just because appetite changes. |
| Recovery supports and preferences | Agree on follow-up and who notices concerning changes. | That weight alone measures well-being. |
| Exact proposed drug | Check its current FDA label and other contraindications. | That professional consensus is itself a new FDA indication. |
The consensus authors recommend screening before GLP-1 initiation and monitoring symptoms in a way that reflects risk. That recommendation is a reason to ask whether a practice has a respectful process, not a directive to self-diagnose or complete an online test as a substitute for care. If an eating-disorder specialist is already involved, the weight-management prescriber should know and coordinate rather than treating the history as a secret to be discovered after an adverse change.2
Keep two safety questions separate
Our FDA mood-warning article addresses the agency’s 2026 population-level review of suicidal-behavior and depression signals. The present article addresses eating behavior, recovery context, and care-team coordination. A reassuring mood-safety review does not answer whether a specific weight-loss program is psychologically appropriate. Conversely, a screening recommendation does not imply that GLP-1 medicines generally cause eating disorders.
The exact product label still governs labeled indications and contraindications. For Wegovy, the current label sets out specific uses, warnings, and contraindications; it does not list “history of any eating disorder” as a categorical exclusion. That absence is not an endorsement of use in a particular person. It makes the professional evaluation more, not less, important.3
What to ask a clinic
The quality of monitoring matters after initiation as well as before it. The Delphi group recommends risk-stratified follow-up, not a single universal questionnaire cadence. A practice can explain which changes in eating behavior, nutrition, mood, or functioning trigger contact and how it will coordinate with a therapist or dietitian when appropriate. This is a clinical-support question, not a demand that every person undergo the same intensive program. The current evidence does not justify promising that appetite suppression will treat an eating disorder, nor assuming it will inevitably cause one.2
Language is part of care. “Just eat less” and a scale-only success target can discourage disclosure of restrictive behaviors or distress. The ADA standard frames obesity evaluation broadly and calls for attention to mental-health conditions. A prospective patient can ask how the practice handles goals other than weight, how confidential history is shared within the team, and whether an existing eating-disorder clinician can participate. The answer can reveal whether the program is equipped for a complex history before any prescription is discussed.1
“How do you assess current and past eating concerns without stigma? Who coordinates with my existing therapist or dietitian if I want that? What changes in eating pattern, mood, or functioning would prompt a review? How will success be evaluated beyond a scale number?” A clinic should be able to explain its actual process, not simply display a prescriber credential or a rapid-approval quiz.
Use Treomark’s medical weight-management hub to compare access and follow-up arrangements. A person can disclose relevant history and still retain a voice in whether medication, another treatment, or no weight-focused intervention fits their goals.
Sources
- American Diabetes Association Professional Practice Committee for Obesity. Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity—2026. Adult obesity evaluation includes validated screening for eating-disorder symptoms and psychosocial context. Accessed .
- Keshen and colleagues, World Psychiatry via NIH PubMed. Consensus-based clinical and research recommendations for use of GLP-1 receptor agonists in the context of eating disorders. 2026 modified Delphi consensus supports history screening and risk-stratified monitoring; consensus is not an FDA label or efficacy trial. Accessed .
- National Library of Medicine DailyMed. WEGOVY prescribing information. Exact product's indications and contraindications; eating-disorder history is not listed as a blanket FDA contraindication. Accessed .